These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30858151)

  • 1. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
    Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
    Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
    Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
    Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
    Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
    Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
    Rotolo A; Caputo VS; Holubova M; Baxan N; Dubois O; Chaudhry MS; Xiao X; Goudevenou K; Pitcher DS; Petevi K; Kachramanoglou C; Iles S; Naresh K; Maher J; Karadimitris A
    Cancer Cell; 2018 Oct; 34(4):596-610.e11. PubMed ID: 30300581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo .
    Bassiri H; Das R; Guan P; Barrett DM; Brennan PJ; Banerjee PP; Wiener SJ; Orange JS; Brenner MB; Grupp SA; Nichols KE
    Cancer Immunol Res; 2014 Jan; 2(1):59-69. PubMed ID: 24563871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins.
    Zhang L; Donda A
    Methods Mol Biol; 2021; 2388():175-180. PubMed ID: 34524672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.
    Lawson V
    Immunology; 2012 Sep; 137(1):20-7. PubMed ID: 22734667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.
    Zhang L; Donda A
    Front Immunol; 2017; 8():1417. PubMed ID: 29163493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
    Guan P; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.
    Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; Hooijberg E; Kramer D; Reurs AW; van den Eertwegh AJ; von Blomberg BM; Scheper RJ; Bontkes HJ
    J Immunol; 2008 Aug; 181(4):2446-54. PubMed ID: 18684935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner.
    Pereira CS; Ribeiro H; Pérez-Cabezas B; Cardoso MT; Alegrete N; Gaspar A; Leão-Teles E; Macedo MF
    Mol Genet Metab; 2018 Sep; 125(1-2):161-167. PubMed ID: 30030044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody.
    Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
    Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
    Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel in vitro invariant natural killer T cell functional assays.
    Balasko A; Graydon C; Fowke KR
    J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine CD8
    Oh S; Lee H; Shin JH; Hong C; Park SH
    Immunol Invest; 2018 Jan; 47(1):89-100. PubMed ID: 29099628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human CD4
    Baiu DC; Sharma A; Schehr JL; Basu J; Smith KA; Ohashi M; Johannsen EC; Kenney SC; Gumperz JE
    Immunology; 2024 Aug; 172(4):627-640. PubMed ID: 38736328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function and expression of CD1d and invariant natural killer T-cell receptor in the cotton rat (Sigmodon hispidus).
    Fichtner AS; Paletta D; Starick L; Schumann RF; Niewiesk S; Herrmann T
    Immunology; 2015 Dec; 146(4):618-29. PubMed ID: 26346465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
    Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
    Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.
    Zeng J; Wang S
    Stem Cells Transl Med; 2014 Jan; 3(1):69-80. PubMed ID: 24292792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.